Cineverse Stock Earnings Reports

Cineverse reported Q2 FY2026 revenue of $12.7M (down 3% YoY) but improved gross margin to 58% (vs. 51% prior year). Adjusted EBITDA was negative $3.7M and net loss $5.5M, driven by ramped SG&A investments to build technology sales, expand theatrical slate marketing, and seed the MicroCo joint venture. A $1.1M licensing fee for The Toxic Avenger will be recognized in future periods; including that timing item, revenue would have been $13.4M (up ~5% YoY). The Toxic Avenger underperformed theatrically but is doing well in ancillaries (VOD, physical, streaming licensing) and is expected to deliver a ~40% IRR; Cineverse retains domestic all-media rights in perpetuity. Management reiterated the low-cost, fan-centric theatrical release model (all-in costs < $5M per film) and highlighted upcoming releases (Silent Night, Deadly Night; Return to Silent Hill; Air Bud Returns) plus the high-profile 20th anniversary domestic deal for Pan’s Labyrinth. The company received a third‑party valuation of its content library at $45M (vs. $3.2M book value). Strategic tech initiatives showed momentum: Matchpoint added 20+ customers recently, closed multiple deals (including onboarding a major studio pilot), launched Matchpoint 3.0 and expanded international integrations, with management targeting it to become the "operating system" for content libraries. MicroCo (high-micro drama JV) is being developed with experienced leadership and VC interest. Balance sheet: $2.3M cash, $5.9M available on a $12.5M facility, no long-term debt, and only 700k warrants outstanding. Management expects the current investments to drive stronger top- and bottom-line results later in FY2026 and into FY2027.